Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pharmacokinetic study of age-dependent clearance of doxorubicin in pediatric patients
2009-011454-17Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Nov 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin in acute lymphoblastic leukemia (ALL), leukemia and Solid tumor (2 arms), sponsored by Universitätsklinikum Münster. Primary endpoint: Doxorubicin clearance difference by age group. Started Nov 2009; status: completed.
02
Drugs
doxorubicin
03
Conditions
acute lymphoblastic leukemia (ALL)leukemiaSolid tumor
Beyond the preview
Go deeper on 2009-011454-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011454-17.